- Home
- AQST vs PRTC Comparison
AQST vs PRTC Comparison
Compare AQST & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- PRTC
- Stock Information
- Founded
- AQST 2004
- PRTC 2015
- Country
- AQST United States
- PRTC United States
- Employees
- AQST N/A
- PRTC N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- PRTC Health Care
- Exchange
- AQST Nasdaq
- PRTC Nasdaq
- Market Cap
- AQST 390.4M
- PRTC 388.6M
- IPO Year
- AQST 2018
- PRTC N/A
- Fundamental
- Price
- AQST $5.18
- PRTC $15.39
- Analyst Decision
- AQST Strong Buy
- PRTC Buy
- Analyst Count
- AQST 7
- PRTC 1
- Target Price
- AQST $10.29
- PRTC $45.00
- AVG Volume (30 Days)
- AQST 2.4M
- PRTC 5.0K
- Earning Date
- AQST 11-03-2025
- PRTC 08-28-2025
- Dividend Yield
- AQST N/A
- PRTC N/A
- EPS Growth
- AQST N/A
- PRTC N/A
- EPS
- AQST N/A
- PRTC 0.20
- Revenue
- AQST $44,132,000.00
- PRTC $6,391,000.00
- Revenue This Year
- AQST N/A
- PRTC N/A
- Revenue Next Year
- AQST $38.71
- PRTC N/A
- P/E Ratio
- AQST N/A
- PRTC $7.29
- Revenue Growth
- AQST N/A
- PRTC 1265.60
- 52 Week Low
- AQST $2.12
- PRTC $13.30
- 52 Week High
- AQST $5.80
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- AQST 68.04
- PRTC 34.46
- Support Level
- AQST $4.75
- PRTC $15.75
- Resistance Level
- AQST $5.27
- PRTC $16.75
- Average True Range (ATR)
- AQST 0.30
- PRTC 0.62
- MACD
- AQST 0.09
- PRTC -0.14
- Stochastic Oscillator
- AQST 75.40
- PRTC 0.00
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.